Contributors

Ken Hallenbeck

Ken Hallenbeck

Ken Hallenbeck earned a Ph.D. in pharmaceutical sciences from the University of California, San Francisco, and now is an early drug-discovery researcher. He serves on the board of directors of ReImagine Science and is the life sciences lead at TerraPrime.

Articles by Ken Hallenbeck

What is better for your career than a publication? A preprint.
Essay

What is better for your career than a publication? A preprint.

Sept. 22, 2022
“Depositing a paper outside of an academic journal allows an author to start promoting the work immediately,” Ken Hallenbeck writes.
It is finally time for post-publication review
Essay

It is finally time for post-publication review

Feb. 3, 2022
The internet has rewritten the rules of print publishing over the last three decades. Why hasn’t it had the same impact on the discussion that follows?
What’s growing in your mouth might change with your health
Journal News

What’s growing in your mouth might change with your health

Dec. 21, 2021
A recent paper in the journal Molecular & Cellular Proteomics takes a tech-enabled deep dive into dental plaques.
Challenging science stereotypes with a video game
Reimagining

Challenging science stereotypes with a video game

July 7, 2021
Imagine a digital game set in a lab that creates a research experience accessible to all and populated by all.
The evolution of proteins from mysteries to medicines
Essay

The evolution of proteins from mysteries to medicines

Feb. 27, 2021
An essay in observance of National Protein Day.
The COVID-19 deluge: Is it time for a new model of data disclosure?
Life in the Lab

Time for a new model of data disclosure?

July 15, 2020
Ken Hallenbeck asserts that a flood of scientific papers related to the pandemic provides an opportunity to review core assumptions of the modern publication model.